ARCS 2017 Annual Conference

Ross Anderson, Evado’s CTO is chairing two sessions at the ARCS 2017 conference on 24th August, 2017.

The Changing Face of Clinical Trials Part One and Part Two will focus on the new trends in wearables, mobiles, eSource and ECRF technology with first hand experience from Industry leaders from HealthKit, Microsoft and Trajan and Monash University.

Updated UniFORM client improves user experience

Evado is thrilled to release new UniFORM client that is optomised to provide an excellent user experience in both desktops and mobile devices. This highly intuitive front end has been designed in collaboration with US clinical experts. Users will be able to navigate through the UniFORM enabled application with minimal clicking.

The latest version of Evado eClinical and eRegistry takes advantage of these new features to dramatically improve a dynamic but simplified user environment

Release of eClinical version 4.3

Evado is pleased to announce the release of eClinical version 4.3, that extends the functionality of the Evado eClinical to including full trial configuration and design tools using the Evado mobile app.

This enables users to have fully access to Evado eClinical configuration and design tools from desktop or iPad/android UniFORM clients.

We have moved

Evado has moved to level 5, 171 Collins Street Melbourne VIC 3000.

Telephone: +61 3 9600 3616
Fax: +61 3 9909 2204


Christmas Greetings!

Team Evado wishes you and yours a safe and Happy Christmas.

The Evado office is now closed until January 9th

For support during the holidays, please email


Report: Australia 60% cheaper than US for clinical trials

With a tax incentive program making clinical trials up to 60% more cost-effective, Australia is a “gateway” to larger studies throughout Asia, says CRO.

According to the report published by Frost & Sullivan, the clinical trials market is expected to reach $615m by 2019, growing at a CAGR of 12%. Additionally, early phase clinical trials have been growing at nearly twice this rate and growth is expected to continue.